ClinicalTrials.gg
TerminatedNCT00261352Updated Apr 22, 2009

GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate

A Phase 3 interventional study of Tesaglitazar and Metformin in Type 2 Diabetes, sponsored by AstraZeneca. Terminated at 152 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-04-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was terminated
The development program has been terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. tesaglitazar · Diabetes Mellitus, Type 2.

Enrollment
4th of 15
1,000 · median 500
Started
2005
with 6 others
Phase 3
11 of 15
none open now
Registered
11th of 15
by date
Lead sponsor
15 of 15
AstraZeneca

Among the 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 7 that started in 2005, is one of 11 in phase 3, and was the 11th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About tesaglitazar

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This is a 24-week study to determine the lipid metabolic effects, safety, and tolerability of tesaglitazar compared with metformin and metformin in combination with fenofibrate in patients with type 2 diabetes and low high-density lipoprotein cholesterol (HDL-C). Improvement in dyslipidemia will be evaluated. The study comprises a 2-week enrollment period, 6-week run-in and a 24-week randomized, double blind, parallel group, multi-center, active controlled (metformin with or without fenofibrate) treatment period and a 3-week follow-up. From visit 2 (run-in), all patients will receive a standardized dose of statin (rosuvastatin)

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of a written
  • Men or women who are >=18 years of age
  • Female patients: , hysterectomized, or if of , using a reliable method of
  • Diagnosed with type 2 diabetes
  • Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • heart failure Class III or IV
  • Treatment with chronic insulin
  • History of or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
  • History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
  • Creatinine levels above the normal range
  • Received any product in other clinical studies within 12 weeks
  • Any abnormality identified on physical examination, laboratory tests or , which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,000 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The change in HDL-C from baseline to the end of the randomized treatment period.

Secondary outcomes

  1. Changes in the following variables from baseline to the end of the randomized treatment period:

  2. Lipid and lipoprotein variables (triglycerides [TG], non-HDL-C, total cholesterol, low-density lipoprotein cholesterol [LDL-C], lipoprotein particle size and concentration, free fatty acid, apolipoprotein [Apo] AI, Apo B, Apo CIII)

  3. Responder analyses for HDL-C, TG, and non-HDL-C according to pre-specified values

  4. The proportion of patients reaching pre-specified target levels for HDL-C, TG, and non-HDL-C

  5. Risk markers for cardiovascular disease (C-reactive protein, insulin, homeostasis model assessment, LDL-C/HDL-C ratio, very-low-density lipoprotein cholesterol/LDL-C ratio, Apo B/Apo AI ratio)

  6. Central obesity (waist/hip ratio)

  7. Pharmacokinetics of tesaglitazar

  8. Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination

07

Study locations

152 sites
  • Research Site
    Fortaleza, CE, Brazil
  • Research Site
    Goiânia, GO, Brazil
  • Research Site
    Porto Alegre, RS, Brazil
  • Research Site
    Curitiba, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Surrey, British Columbia, Canada
  • Research Site
    Bay Roberts, Newfoundland and Labrador, Canada
  • Research Site
    Mount Pearl, Newfoundland and Labrador, Canada
  • Research Site
    St. John's, Newfoundland and Labrador, Canada
  • Research Site
    Bolton, Ontario, Canada
  • Research Site
    Brampton, Ontario, Canada
  • Research Site
    Etobicoke, Ontario, Canada
  • Research Site
    Hastings, Ontario, Canada
  • Research Site
    Kingston, Ontario, Canada
  • Research Site
    Kitchener, Ontario, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    Mississauga, Ontario, Canada
  • Research Site
    Napanee, Ontario, Canada
  • Research Site
    Newboro, Ontario, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Pointe-Claire, Quebec, Canada
  • Research Site
    Sherbrooke, Quebec, Canada
  • Research Site
    Helsinki, Finland
  • Research Site
    Kuopio, Finland
  • Research Site
    Lahti, Finland
  • Research Site
    Mikkeli, Finland
  • Research Site
    Oulu, Finland
  • Research Site
    Porvoo, Finland
  • Research Site
    Savonlinna, Finland
  • Research Site
    Seinäjoki, Finland
  • Research Site
    Suonenjoki, Finland
  • Research Site
    Tampere, Finland
  • Research Site
    Turku, Finland
  • Research Site
    Vaasa, Finland
  • Research Site
    Aix En Provence, France
  • Research Site
    Ambriere Les Vallees, France
  • Research Site
    Beziers, France
  • Research Site
    Briey Cedex, France
  • Research Site
    Broglie, France
  • Research Site
    Chateau Gontier, France
  • Research Site
    Cremeaux, France
  • Research Site
    Falaise, France
  • Research Site
    Fontaine Saint Martin, France
  • Research Site
    Freyming Merlebach, France
  • Research Site
    GAN, France
  • Research Site
    Hyeres, France
  • Research Site
    Jarny, France
  • Research Site
    Jort, France
  • Research Site
    L'aigle, France
  • Research Site
    Lambersart, France
  • Research Site
    Le Lavandou, France
  • Research Site
    Lille, France
  • Research Site
    Lomme Cedex, France
  • Research Site
    Marange Silvange, France
  • Research Site
    Marignane, France
  • Research Site
    Mars La Tour, France
  • Research Site
    Martigues, France
  • Research Site
    Mayenne, France
  • Research Site
    Metz, France
  • Research Site
    Mondelange, France
  • Research Site
    Montbrison, France
  • Research Site
    Montpellier, France
  • Research Site
    Moutiers, France
  • Research Site
    Nantes Cedex 01, France
  • Research Site
    Nantes Cedex 1, France
  • Research Site
    Paris, France
  • Research Site
    Poitiers, France
  • Research Site
    Roanne, France
  • Research Site
    Roquevaire, France
  • Research Site
    Rugles, France
  • Research Site
    Saint Chamond, France
  • Research Site
    Saint Jean de Luz, France
  • Research Site
    Tantonville, France
  • Research Site
    Heidelberg, Baden-Württemberg, Germany
  • Research Site
    Stuttgart, Baden-Württemberg, Germany
  • Research Site
    München, Bayern, Germany
  • Research Site
    Frankfurt, Hessen, Germany
  • Research Site
    Hannover, Niedersachsen, Germany
  • Research Site
    Düsseldorf, Nordrhein-Westfalen, Germany
  • Research Site
    Münster, Nordrhein-Westfalen, Germany
  • Research Site
    Dresden, Sachsen, Germany
  • Research Site
    Aschaffenburg, Germany
  • Research Site
    Beckum, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Düsseldorf, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Gelnhausen, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Heilbronn, Germany
  • Research Site
    Künzing, Germany
  • Research Site
    Nürnberg, Germany
  • Research Site
    Pirna, Germany
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Shatin, Hong Kong
  • Research Site
    Balatonfüred, Hungary
  • Research Site
    Budapest, Hungary

Showing the first 100 of 152 sites across 18 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2005
First posted
Dec 5, 2005
Start
Mar 2005
CompletionActual
Dec 2006
Last update
Apr 22, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00261352
Lead sponsor
AstraZeneca
First posted
Dec 5, 2005
Start date
Mar 2005
Completion
Dec 2006
Last update
Apr 22, 2009

Study contacts

AstraZeneca Galida Medical Science DIrector, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tesaglitazar · Metformin · Fenofibrate

Start the discussion